When was Tessera Therapeutics founded?

Tessera Therapeutics was founded in 2017 and raised its 1st funding round within a year of its incorporation.

Where is Tessera Therapeutics located?

Tessera Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

How many employees does Tessera Therapeutics have?

As of Jul 31, 2026, the latest employee count at Tessera Therapeutics is 191.

Is Tessera Therapeutics a funded company?

Tessera Therapeutics is a funded company, having raised a total of $610M across 3 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Dec 20, 2017.

When was the latest funding round of Tessera Therapeutics?

Tessera Therapeutics' latest funding was a $***** Series C round on Apr 19, 2022, with participation from 10 investors. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $1.62B in funding in 2026 to date.

Where does Tessera Therapeutics rank among its competitors?

Tessera Therapeutics ranks 10th amongst 972 active competitors, of which 148 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was eGenesis, which secured $14M in Aug, 2026.

Who are the top competitors of Tessera Therapeutics?

Tessera Therapeutics' top competitors include Strand Life Sciences, Beam Therapeutics and eGenesis. Among them, eGenesis secured the most recent funding round in August, 2026.

Tessera Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Tessera Therapeutics is a provider of new genome engineering technology for treating multiple diseases. It offers a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. It offers RNA gene writings that can change base pairs, make small insertions or deletions, and integrate entire genes into the genome.

Website: tesseratherapeutics.com
Social
Email ID: *****@tesseratx.com
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2017

Location

Cambridge, United States

Stage

Series C

Total Funding

$610M in 3 rounds

Latest Funding Round

Series C, Apr 19, 2022, $*****

Investors

Temasek & 23 more

Ranked

10^th among 972 active competitors

Employee Count

191 as on Jul 31, 2026

Similar Companies

Beam Therapeutics & 325 more

View Tessera Therapeutics' full profile

Tessera Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
TESSERA THERAPEUTICS, INC CIN: 831788350 , United States, Active	Dec 31, 1999	-	308 (As on Dec 31, 2024)	-

Tessera Therapeutics has raised a total funding of $610M over 3 rounds. Its first funding round was on Dec 20, 2017. Its latest funding round was a Series C round on Apr 19, 2022 for $*****. 10 investors participated in its latest round. Tessera Therapeutics has 24 institutional investors.

Here is the list of recent funding rounds of Tessera Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 19, 2022	3660677	Series C	5603377	4370800	5372619	2837069
Jan 12, 2021	3574005	Series B	7225479	1374253	5911984	Qatar Investment Authority
Dec 20, 2017	8009169	Series B	5652540	1306408	Temasek	EDBI & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Tessera Therapeutics's funding rounds and investors

The founders of Tessera Therapeutics is Robert Citorik.

Here are the details of Tessera Therapeutics' key team members:

Robert Citorik: Co-Founder & Director of Tessera Therapeutics.

View details of Tessera Therapeutics's Founder profiles and Board Members

Tessera Therapeutics' employee count trend

Tessera Therapeutics has 191 employees as of Jul 26. Here is Tessera Therapeutics's employee count trend over the years:

Employee count trend for Tessera Therapeutics

Uncover Tessera Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Tessera Therapeutics include Strand Life Sciences, Beam Therapeutics and eGenesis. Here is the list of Top 10 competitors of Tessera Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Strand Life Sciences 2000, Bengaluru (India), Acquired	Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery	$34.9M	Biomark Capital, WestBridge Capital & 92 others	74/100
2nd	Beam Therapeutics 2017, Cambridge (United States), Public	Developer of gene therapy using CRISPR base editing to treat diseases	$222M	Redmile Group, Cormorant-asset & 16 others	71/100
3rd	eGenesis 2015, Cambridge (United States), Series D	Developer of a gene transplantation platform for humanizing pig cells	$495M	Monashee Investment Management, Farallon Capital Management ... & 31 others	65/100
4th	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, Decheng Capital & 34 others	64/100
5th	Scribe Therapeutics 2018, Alameda (United States), Public	Developer of a gene-editing platform using CRISPR technology	$120M	Avoro Capital, Andreessen Horowitz & 7 others	65/100
6th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, RA Capital Management & 22 others	65/100
7th	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Artis Ventures, Illumina & 13 others	64/100
8th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
9th	BGI 1999, Shenzhen (China), Public	Provider of services in genome sequencing	-	Sequoia Capital China, Yunfeng Capital & 15 others	64/100
10th	Tessera Therapeutics 2017, Cambridge (United States), Series C	Provider of new genome engineering technology for treating multiple diseases	$610M	T. Rowe Price, Foresite Capital & 22 others	63/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Tessera Therapeutics's competitors? Click here to see the top ones

Tessera Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Tessera Therapeutics's sector:

Free

Internet of Things - Sector Report

Edition: August, 2026 (80 Pages)

View all reports related to Tessera Therapeutics

Media has covered Tessera Therapeutics for a total of 10 events in the last 1 year, 5 of them have been about company updates and 2 about partnerships.